Pulmonary arterial hypertension is a progressive disease in which the small arteries of the lungs narrow, stiffen, and sometimes close off entirely, forcing the right side of the heart to pump against dangerously high resistance. It is defined by specific pressure measurements taken during right heart catheterization: a mean pulmonary artery pressure above 20 mm Hg, a wedge pressure of 15 mm Hg or lower, and a pulmonary vascular resistance of 3 Wood units or more.1JAMA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review Unlike more common forms of pulmonary hypertension caused by left heart disease or chronic lung conditions, PAH originates in the lung blood vessels themselves, and it carries a distinct treatment pathway that has changed dramatically over the past two decades.
How PAH Differs From Other Forms of Pulmonary Hypertension
Pulmonary hypertension is an umbrella term split into five clinical groups. Group 1 is PAH. Groups 2 through 5 cover pulmonary hypertension driven by left heart disease, lung disease or low oxygen levels, chronic blood clots in the lungs, and miscellaneous or unclear causes, respectively. The distinction matters because each group has a different underlying problem and responds to different treatments. Giving PAH-specific drugs to someone whose high lung pressures stem from, say, a weak left ventricle can actually make things worse by flooding a heart chamber that is already overloaded.
Among adults, Groups 2 and 3 are the most common forms of pulmonary hypertension and carry the highest mortality. Group 1 PAH, while less prevalent overall, tends to strike younger people and is the most common form in children, accounting for about two-thirds of pediatric pulmonary hypertension cases.2PubMed Central. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada This is one reason PAH research receives outsized attention relative to its numbers: it affects people in the prime of life, and it remains life-threatening without aggressive treatment.
What Happens Inside the Lung Arteries
In a healthy lung, the small pulmonary arteries are thin-walled and compliant, offering very little resistance to blood flow. In PAH, three layers of these artery walls thicken and remodel. The inner lining of endothelial cells proliferates. The smooth muscle in the middle layer grows excessively. And the outer connective tissue layer stiffens. The result is a progressively narrower channel for blood to pass through.
In advanced disease, some arteries develop complex growths called plexiform lesions, tangled clusters of new vascular channels that are a hallmark of severe PAH. These lesions are not uniform. Imaging studies have identified at least four distinct types, including some that appear to form bypass routes connecting pulmonary arteries to the bronchial circulation, and others that represent attempts to recanalize completely blocked vessels.3PubMed Central. Distinct types of plexiform lesions identified by synchrotron-based phase-contrast micro-CT The lesions are lined by continuously dividing endothelial cells and surrounded by smooth muscle, with a molecular signature that includes markers of growth factor signaling and tissue remodeling.4PubMed Central. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment Experimental models in rats have reproduced lesions that look virtually identical to the human versions, which has given researchers a way to study how these structures form and, potentially, how to prevent them.5PubMed. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension
Three Molecular Pathways That Drive the Disease
The vascular remodeling in PAH is not caused by a single malfunction. Three major signaling pathways in the blood vessel lining go wrong simultaneously, and each one is now a drug target.
The first involves endothelin-1, a molecule produced by endothelial cells that is one of the most potent constrictors of blood vessels known. In healthy arteries, endothelin-1 is balanced by relaxing signals. In PAH, endothelin-1 production ramps up, causing the smooth muscle in the artery walls to contract and proliferate.6PubMed. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension Endothelin-1 acts through two receptor types on smooth muscle cells to drive both vasoconstriction and cell growth.7PubMed. The endothelin system in pulmonary arterial hypertension
The second pathway involves nitric oxide, a gas that healthy endothelial cells release to relax blood vessels and prevent clotting. In PAH, the availability of nitric oxide drops, removing a key brake on vasoconstriction.8PubMed. The Nitric Oxide Pathway in Pulmonary Vascular Disease Drugs that boost the downstream effects of nitric oxide have become a pillar of PAH treatment.
The third pathway involves prostacyclin, another molecule made by endothelial cells that normally dilates blood vessels, keeps smooth muscle from growing too quickly, and prevents blood platelets from clumping. Prostacyclin production is reduced in PAH, and drugs that mimic or enhance its action represent one of the oldest and most established treatment classes for the disease.9PubMed. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review
The Genetic Side of PAH
Not everyone with PAH has a genetic cause, but when PAH runs in families, the most commonly mutated gene is BMPR2, which encodes a receptor involved in controlling cell growth in blood vessels.10PubMed Central. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis A large catalog of over 140 distinct coding mutations has been compiled, and the majority of them effectively shut down one copy of the gene, leaving a person with only half the normal amount of functioning receptor. This “half dose” mechanism appears to be what predisposes carriers to disease.11PubMed. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension Larger-scale gene rearrangements (whole chunks of the gene deleted or shuffled) account for roughly 12% of familial cases and about 5% of cases that appear to arise spontaneously.12PubMed. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension
Carrying a BMPR2 mutation does not guarantee you will develop PAH. Penetrance is incomplete, meaning many carriers live their entire lives without symptoms. There is also a sex bias: women who carry the mutation are more likely to develop the disease than men, though the reasons remain unclear. This incomplete penetrance suggests that additional triggers, whether environmental, hormonal, or involving other genes, are needed to push a genetically vulnerable person into overt disease.
Drugs, Toxins, and Other Triggers
Some cases of PAH are linked to exposures rather than genetics. Methamphetamine use has been identified as a definite risk factor for developing PAH, a connection established through epidemiological studies that moved the association from “possible” to confirmed.13PubMed Central. Methamphetamine and the risk of pulmonary arterial hypertension Certain appetite suppressants, particularly fenfluramine-based drugs withdrawn from the market decades ago, were among the earliest recognized drug triggers. HIV infection, portal hypertension from liver disease, and congenital heart defects are other well-established associations. In parts of Asia, a relatively high proportion of PAH cases are linked to congenital heart disease and connective tissue conditions like lupus, compared with patterns seen in Western countries.14PubMed Central. Pulmonary Hypertension Definition, Classification, and Epidemiology in Asia
Getting to a Diagnosis
PAH is notoriously slow to diagnose. Its early symptoms, such as breathlessness during exertion, fatigue, and occasional dizziness, overlap with dozens of common conditions. Many patients see multiple doctors over months or years before the correct diagnosis is made. An echocardiogram can raise suspicion by estimating pressures in the right side of the heart, but it cannot confirm the diagnosis. The definitive test is right heart catheterization, a procedure in which a thin tube is threaded through a vein into the heart and pulmonary artery to directly measure pressures and blood flow.15PubMed Central. Right heart catheterisation: best practice and pitfalls in pulmonary hypertension
An important part of the diagnostic workup is ruling out chronic blood clots in the lungs, a condition called chronic thromboembolic pulmonary hypertension. This matters because CTEPH is potentially curable with surgery, whereas PAH is not. The preferred screening test is a ventilation-perfusion lung scan, which has a sensitivity in the range of 90 to 100% and specificity of 94 to 100% for picking up CTEPH, outperforming CT angiography for this purpose.16European Respiratory Review. Diagnosis of chronic thromboembolic pulmonary hypertension – Section: Ventilation/perfusion scintigraphy
Why the Right Ventricle Decides Your Fate
In PAH, the right ventricle faces a workload it was never designed for. A healthy right ventricle pumps blood into a low-pressure system. When that system stiffens and narrows, the right ventricle initially compensates by thickening its walls, a process called hypertrophy. For a time, this adaptation maintains cardiac output and the patient may feel relatively stable.
But sustained pressure overload alone does not tell the whole story. Research in animal models shows that isolated pressure overload causes the right ventricle to thicken without necessarily failing. What pushes it toward failure is the combination of high pressure with vascular injury: the same disease process happening in the lung arteries appears to impair the right ventricle’s own blood supply. The failing right ventricle shows cell death, scarring, reduced capillary density, and a paradoxical drop in growth factor signaling even as the heart muscle is starved for oxygen.17PubMed. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure The heart’s ability to respond to stress hormones also breaks down, with the receptors that normally translate adrenaline into stronger contractions becoming desensitized.18PubMed Central. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure Ultimately, right ventricular failure is what kills most patients with PAH, making the health of this chamber the single most important prognostic factor.
Current Treatment Strategies
Modern PAH treatment targets the three molecular pathways described earlier. Endothelin receptor antagonists (drugs like bosentan, ambrisentan, and macitentan) block endothelin-1 from reaching its receptors. A Cochrane review of 12 randomized trials found that these drugs improved six-minute walking distance by about 34 meters on average compared with placebo, improved functional class in more patients, and reduced the odds of clinical deterioration.19PubMed Central. Endothelin receptor antagonists for pulmonary arterial hypertension Drugs that boost nitric oxide signaling, such as the phosphodiesterase-5 inhibitors sildenafil and tadalafil, and the soluble guanylate cyclase stimulator riociguat, form a second pillar. Prostacyclin-pathway drugs, ranging from continuous intravenous infusions to inhaled and oral formulations, make up the third.
The evidence strongly favors combining drugs from different pathways rather than starting with just one. The landmark AMBITION trial showed that starting patients on both an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor from the outset cut the risk of clinical failure by about half compared with using either drug alone.20PubMed Central. Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION Upfront combination therapy is now standard practice for most newly diagnosed patients.
The newest addition to the treatment landscape is sotatercept, a first-in-class drug that works through an entirely different mechanism. Rather than targeting vasoconstriction or vascular tone, sotatercept acts as a trap for activins, signaling molecules that promote abnormal cell growth in the pulmonary vessels. By intercepting these growth signals, it aims to rebalance the pro-growth and anti-growth pathways that have tipped in favor of vascular remodeling.21PubMed Central. Evaluating sotatercept in the treatment of pulmonary arterial hypertension Experimental work also suggests that sotatercept has anti-inflammatory properties that may contribute to its effects on the disease.22Scientific Reports. Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension Sotatercept represents a genuine shift in how PAH is treated: for the first time, there is a drug that attempts to address the underlying vascular overgrowth rather than just relaxing blood vessels.
Surgical and Interventional Options
For patients with severe PAH who are deteriorating despite maximum medical therapy, lung transplantation remains the ultimate option. But the wait for donor organs is long, and some patients, especially children, need a bridge strategy. Two interventional approaches have emerged for this purpose.
Atrial septostomy involves creating a small hole between the right and left atria of the heart. This allows some blood to bypass the congested lungs, relieving pressure on the right ventricle at the cost of slightly lower oxygen levels. The Potts shunt takes a similar concept further by surgically connecting the left pulmonary artery to the descending aorta, directly offloading the right ventricle. Case reports and small series in children with suprasystemic PAH have shown that the Potts shunt can reduce symptoms and even allow some PAH medications to be scaled back.23PubMed. Beyond transplant: Roles of atrial septostomy and Potts shunt in pediatric pulmonary hypertension 24PubMed Central. Potts shunt in patients with primary pulmonary hypertension These are palliative procedures, not cures, but for children facing years on a transplant list, they can meaningfully extend functional life.
PAH in the Setting of Connective Tissue Disease
Systemic sclerosis (scleroderma) is the connective tissue disease most closely linked to PAH, and PAH developing in this context is among the most difficult to treat. Survival data paint a sobering picture: in one cohort, three-year survival from the time of PAH diagnosis was about 56%, and the overall death rate was roughly six times what would be expected in the general population matched for age and sex.25Annals of the Rheumatic Diseases. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era Male sex emerged as a particularly strong independent predictor of worse survival in this population. Combination PAH therapy, especially when paired with anticoagulation, offered a meaningful survival advantage over monotherapy.26PubMed Central. Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension
Because scleroderma-associated PAH responds less well to treatment than idiopathic PAH, screening programs have become standard at scleroderma clinics. Annual echocardiography, lung function testing, and biomarker monitoring aim to catch rising pulmonary pressures before symptoms develop. Earlier diagnosis in this group translates to starting treatment at a less advanced stage, which is one of the few modifiable factors that clearly improves outcomes.
Pediatric PAH Is Its Own Entity
PAH in children shares the broad hemodynamic definition used in adults, but the causes and clinical picture often look quite different. Altered lung development, whether from prematurity, congenital diaphragmatic hernia, or other conditions that disrupt fetal or neonatal lung growth, is a major driver of pediatric pulmonary hypertension that has no real counterpart in adults.27PubMed Central. Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment Treatment in children therefore goes beyond vasodilators to include strategies aimed at promoting lung growth: careful ventilator management, maintaining appropriate oxygen and carbon dioxide levels, good nutrition, and treating comorbidities like airway disease and reflux.
The lack of randomized controlled trial data in children is a persistent problem. Most pediatric PAH drugs are used based on extrapolation from adult trials, with dosing adjusted by weight and clinical response. The 6th World Symposium on Pulmonary Hypertension acknowledged this gap and called for better goal-oriented treatment frameworks specific to children.28European Respiratory Journal. Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management On the brighter side, five-year mortality in children with Group 1 pulmonary hypertension is lower than in adults, around 21% in one population-based study.29PubMed Central. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada
Pregnancy and PAH
Pregnancy in a woman with PAH is one of the highest-risk scenarios in cardiology. Even with modern therapies, maternal mortality remains elevated, with the greatest danger concentrated in the weeks after delivery. Current European guidelines explicitly recommend that women with PAH avoid pregnancy, and counseling about contraception is considered a standard part of care from the moment of diagnosis.30PubMed Central. Pregnancy in pulmonary arterial hypertension If a woman with PAH does become pregnant, early termination is discussed, and those who choose to continue are managed at specialized centers with multidisciplinary teams prepared for high-risk delivery and the precarious postpartum period. The physiological reasons are straightforward: pregnancy increases blood volume and cardiac output by roughly 30 to 50%, demands the right ventricle cannot safely meet when pulmonary pressures are already high.
Exercise in PAH
For years, patients with PAH were told to avoid exertion. That advice has shifted. A meta-analysis of exercise training programs found that supervised exercise improved six-minute walking distance by about 53 meters, boosted peak oxygen uptake, lowered pulmonary artery systolic pressure by a few points, and improved quality-of-life scores, all without major adverse events.31PubMed. Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis A large European randomized trial confirmed these findings, reporting a 34-meter improvement in walking distance along with gains in mental health scores and functional class.32European Heart Journal. Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled trial The key qualifier is “supervised.” These programs are typically designed by rehabilitation specialists, start at low intensity, and ramp up gradually. Unsupervised high-intensity exercise still carries risks in this population.
The Mental Health Burden
Living with PAH takes a psychological toll that is often underappreciated by medical teams focused on hemodynamics and drug titration. Depression and anxiety are common, and their severity tracks closely with reductions in quality of life across both physical and mental domains.33PubMed Central. Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Patients with moderate to severe depression score worse on virtually every quality-of-life measure compared with those without significant mood symptoms.34PubMed Central. Anxiety and depression in patients with pulmonary hypertension: impact and management challenges – Section: Clinical importance of psychologic symptoms The disease imposes daily constraints: activity limitations, complex medication regimens (some requiring continuous intravenous pumps), frequent hospital visits, and for women, the inability to safely carry a pregnancy. Screening for depression and anxiety, and integrating mental health support into PAH care, remain inconsistently practiced despite growing evidence that untreated psychological distress worsens outcomes.
Cost and Access Disparities
PAH medications are among the most expensive in all of medicine, with average healthcare costs estimated between roughly $2,000 and $9,300 per patient per month.35PubMed Central. Global, regional, and national burden of pulmonary arterial hypertension from 1990 to 2021 – Section: Discussion In lower-income countries, the combination of high drug costs, limited access to specialist centers, and fewer diagnostic tools means that more patients go undiagnosed or are diagnosed too late to benefit from therapy. Underdiagnosis rates are higher in these settings, and patients with rapidly progressive disease may die before ever receiving targeted treatment. Even within high-income countries, insurance coverage, geographic distance from a pulmonary hypertension center, and socioeconomic barriers create meaningful disparities in who benefits from the treatments that clinical trials have proven effective.